News

The institute granted the funding under its CIRM 2.0 program, which is designed to speed up the development of stem cell-based treatments for people with unmet medical requirements.

In its final draft guidance, the regulator recommended Zydelig for patients whose leukaemia has come back less than two years following earlier treatment. Earlier this year, NICE asked

The European Medicines Agency’s Committee for Medicinal Products for Human Use gives its recommendations for marketing authorization to drugs to the European Commission (EC). The commission is expected

These studies are expected to be completed within the next two months. These studies are anticipated to produce purified recombinant protein and conduct an orthogonal assay to validate

A United States patent entitled "Erythrocytes Containing Arginine Deiminase" has been issued by the U.S. Patent and Trademark Office (USPTO) as U.S. Patent No. 9,125,876. It covers the

Keryx carried out a phase 2, non-dialysis study and a 58-week, phase 3 registration trial on about 1900 patients. The company said in the phase 3 trial, ferric

Enrolment in the clinical trial is expected to commence in the next few weeks. In its planned Phase 1/2 clinical trial, ESSA intends to demonstrate the safety, tolerability,

The survey was conducted online by Harris Poll on behalf of the CHPA Educational Foundation in February 2015 among 2,002 U.S. adults 18 and older who have used

Under the study, Amgen and Allergan evaluated the efficacy and safety of ABP 215 compared with Genentech’s Avastin (bevacizumab) in patients with advanced non-small cell lung cancer. The